Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

America’s new approach to enforcing a decades-old law outlawing foreign bribery means fresh risk for Canadian multinationals, ...

Williams County Public Library will hold a retirement reception in honor of Stryker Library Assistant Linda Woodall.

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company ...

Bill also believe they may have the numbers to see it off the proposed decriminalisation in England and Wales.

Stryker stock ended Monday with a flatline finish, but the day itself was anything but boring. The price action played out ...

Investing.com -- Moody’s Ratings upgraded Stryker Corporation (NYSE: SYK )’s senior unsecured notes to A3 from Baa1 on Wednesday, while revising the company’s outlook to stable from positive.

The ROBO Global Healthcare Technology & Innovation Index offers unique, targeted exposure to innovators. Click to read.

Stryker stock started the week limping, gapping down at the open and slipping to a low of $373.36 before showing a mild ...